Aadi Bioscience Appoints New Chief Medical Officer
Ticker: WHWK · Form: 8-K · Filed: Sep 30, 2024 · CIK: 1422142
Sentiment: neutral
Topics: executive-appointment, biotech, personnel
TL;DR
Aadi Bioscience just hired a new CMO with big pharma oncology experience. Big moves ahead?
AI Summary
On September 26, 2024, Aadi Bioscience, Inc. announced the appointment of Dr. Michael J. Nally as its new Chief Medical Officer. Dr. Nally brings extensive experience in oncology drug development, previously holding leadership roles at companies like Astellas Pharma and Pfizer.
Why It Matters
The appointment of a new Chief Medical Officer with a strong background in oncology drug development could signal a renewed focus on advancing Aadi Bioscience's pipeline and potentially impact the company's future clinical trial strategies and regulatory submissions.
Risk Assessment
Risk Level: medium — The appointment of a key executive like a CMO is significant for a biotech company, carrying implications for future strategy and execution, but does not represent an immediate financial or operational crisis.
Key Players & Entities
- Aadi Bioscience, Inc. (company) — Registrant
- Dr. Michael J. Nally (person) — Newly appointed Chief Medical Officer
- Astellas Pharma (company) — Previous employer of Dr. Nally
- Pfizer (company) — Previous employer of Dr. Nally
FAQ
What is the effective date of Dr. Michael J. Nally's appointment as Chief Medical Officer?
The filing does not explicitly state an effective date for Dr. Nally's appointment, but the report is dated September 26, 2024, indicating the announcement was made on or around this date.
What previous companies has Dr. Michael J. Nally worked for?
Dr. Nally has held leadership roles at Astellas Pharma and Pfizer.
What is Aadi Bioscience, Inc.'s primary business?
Aadi Bioscience, Inc. is involved in the pharmaceutical preparations industry, as indicated by its SIC code [2834].
What is the address of Aadi Bioscience, Inc.'s principal executive offices?
The address is 17383 Sunset Boulevard, Suite A250, Pacific Palisades, California, 90272.
What was Aadi Bioscience, Inc. formerly known as?
Aadi Bioscience, Inc. was formerly known as Aerpio Pharmaceuticals, Inc. and Zeta Acquisition Corp II.
Filing Stats: 469 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-09-30 06:06:52
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share AADI The Nasdaq Stock Mar
Filing Documents
- d871823d8k.htm (8-K) — 22KB
- 0001193125-24-228322.txt ( ) — 140KB
- aadi-20240926.xsd (EX-101.SCH) — 3KB
- aadi-20240926_lab.xml (EX-101.LAB) — 18KB
- aadi-20240926_pre.xml (EX-101.PRE) — 11KB
- d871823d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AADI BIOSCIENCE, INC. Dated: September 30, 2024 /s/ Scott Giacobello Scott Giacobello Chief Financial Officer